HepG2 cells were exposed to cisplatin (DDP, Sigma-Aldrich, Germany) at the concentration of 0.1 mM, and followed by a sub-culture in the RPMI-1640 medium containing stepwise-increasing concentrations of DDP (0.1, 0.5, 1.0, 2.0 and 3.0 mM), timely. Finally, viable HepG2 cells in the culture medium with a high concentration of DDP (2.0 mM) were selected and defined as cisplatin-resistant HepG2 cells (HepG2/DDP).

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.